Novartis Benefits From Lack of Generic Challenge
April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."
Most Recent Videos
Soylent: The Food of the Future?
30:33 - Rob Rhinehart, Soylent's chief executive officer, discusses the company's quest to disrupt the food industry. He speaks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)